Medical devices

Energous Partner NewSound Receives FCC Approval for WattUp®-enabled Hearing Aid

Technology, Mobile, Wireless, Medical devices, Semiconductor, Audio, Video, Hardware, Health, Electronic design automation, General Health, Otology, Hearing aid, Hearing, Neuroscience, Branches of biology

Tuesday, October 27, 2020 - 10:30am

Today Energous Corporation (Nasdaq: WATT), the developer of WattUp, a revolutionary wireless charging 2.0 technology, announced that NewSound, a hearing instruments company and Energous partner, has received FCC approval for its WattUp-enabled Primo W next-generation hearing aid.

Key Points:

Today Energous Corporation (Nasdaq: WATT), the developer of WattUp, a revolutionary wireless charging 2.0 technology, announced that NewSound, a hearing instruments company and Energous partner, has received FCC approval for its WattUp-enabled Primo W next-generation hearing aid.
View the full release here: https://www.businesswire.com/news/home/20201027005463/en/
NewSound received FCC approval for its WattUp-enabled Primo W next-generation hearing aid (Photo: Business Wire)
The NewSound Primo W hearing aid is powered by Energous radio frequency-based wireless charging technology, which supports charging of a large variety of devices , including very small, rounded devices such as behind-the-ear and in-the-ear hearing aids.
The NewSound Primo W hearing aid supports a variety of advanced features, including:
SOUNDWEAR App control for charging status, battery monitoring, self-hearing check, program management, remote-fit and more
All-in-one case for easy storage, recharging, UV sanitizing and dehumidifying
Securing FCC approval for our Primo W hearing aid solution is a major milestone along our journey to providing our customers with best-in-class hearing products that amplify their hearing experience, said Boyang Li, CTO of NewSound.
To learn more about NewSound and the Primo W hearing aid, please visit usnewsound.com .

CN Bio to Provide Drug Metabolism and Safety Toxicity Testing Services

Health, Medical devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Toxicology, Medical specialties, Health, Hepatology, Pharmacokinetics, Pharmacology, Metabolism, Hepatotoxicity, Toxicity, Drug metabolism, Drug discovery

Tuesday, October 27, 2020 - 9:43am

CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services.

Key Points:

CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services.
Liver toxicity is a principal safety concern during drug discovery and development, with the potential to terminate expensive clinical trials already underway.
CN Bios extended portfolio of services offers solutions to many existing workflow challenges including: drug metabolism testing, to study the human metabolism of lead candidates, identify metabolites and correlation with cell health - even for low clearance compounds, and safety toxicity testing, to provide in-depth analysis of acute or chronic drug-induced liver injury using a wide range of endpoints to determine causality and mechanism of toxicity.
Through our enhanced drug metabolism and safety toxicity testing services, we enable scientists to take a step beyond what is currently possible with 2D cell culture and animal studies to improve their chances of clinical success.

Insights & Forecast With Potential Impact of COVID-19 - Global MEMS Microphone Market 2020-2024 | Increased Penetration of MEMS Technology in Hearing Aids to Boost Market Growth | Technavio

Consumer electronics, Health, Medical devices, Technology, Audio, Video, General Health, Hardware, Articles, Health, Impact of the COVID-19 pandemic, Microphone, COVID-19 pandemic, Contemporary history, Microelectromechanical systems

Tuesday, October 27, 2020 - 5:00am

The report offers a detailed analysis of the impact of COVID-19 pandemic on the MEMS microphone market in optimistic, probable, and pessimistic forecast scenarios.

Key Points:

The report offers a detailed analysis of the impact of COVID-19 pandemic on the MEMS microphone market in optimistic, probable, and pessimistic forecast scenarios.
View the full release here: https://www.businesswire.com/news/home/20201026005871/en/
Technavio has announced its latest market research report titled Global MEMS Microphone Market 2020-2024 (Graphic: Business Wire).
The MEMS microphone market will witness Negative and Inferior impact during the forecast period owing to the widespread growth of the COVID-19 pandemic.
Get report snapshot here to get detailed market share analysis of market participants during COVID-19 lockdown: https://www.technavio.com/report/ MEMS microphone market-industry-analysis
MEMS Microphone is segmented as below:

Apheresis Devices Market 2020-2024 | Growing Number of Surgical Procedures to Boost Growth | Technavio

Hospitals, Health, Surgery, Medical devices, Business process, Clinical medicine, Medicine, Market analysis, Market research, Apheresis

Tuesday, October 27, 2020 - 1:30am

View the full release here: https://www.businesswire.com/news/home/20201026005768/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20201026005768/en/
Technavio has announced its latest market research report titled Global Apheresis Devices Market 2020-2024 (Graphic: Business Wire)
The report on the apheresis devices market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
Download Free Sample Report on COVID-19 Recovery Analysis
The apheresis devices market analysis include product segment and geographic landscapes.
This study identifies the technological advances as one of the prime reasons driving the apheresis devices market growth during the next few years.

Hernia Repair Devices Market will Exhibit Positive Impact during 2020-2024 due to Increasing Prevalence of Hernia | Technavio

Medical devices, Health, Clinical medicine, Medicine, Hernias, Digestive system surgery, Hernia repair

Monday, October 26, 2020 - 11:30pm

Technavio has been monitoring the hernia repair devices market, operating under the healthcare sector.

Key Points:

Technavio has been monitoring the hernia repair devices market, operating under the healthcare sector.
The latest report on the hernia repair devices market, 2020-2024 estimates it to register an incremental growth of $ 1.46 bn, at a CAGR of over 5% during the forecast period.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
Download a Free Sample Report on COVID-19 Impacts
Hernia Repair Devices Market 2020-2024: Segmentation
Hernia Repair Devices Market is segmented as below:

Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue

Diabetes, Health, Medical devices, Dexcom, Electronic Arts, Doubleday, California, Video game companies, Companies

Monday, October 26, 2020 - 8:42pm

Rick joined Dexcom in 2009 and has built a world-class sales organization that allowed Dexcom to grow from approximately $49 million in reported revenue in his first full year to its current global commercial success.

Key Points:

Rick joined Dexcom in 2009 and has built a world-class sales organization that allowed Dexcom to grow from approximately $49 million in reported revenue in his first full year to its current global commercial success.
In conjunction with the announcement of Mr. Doubledays retirement and to celebrate Ricks accomplishments that include another record quarter, the company today announced select preliminary financial results for the third quarter ended September 30, 2020.
Dexcom achieved half a billion dollars in revenue in the third quarter, with revenues of $500.9 million, representing 26% growth over the third quarter of 2019.
Rick Doubleday has proven himself to be an extraordinary leader throughout his time at Dexcom, which includes yet another record result in the third quarter of 2020, said Kevin Sayer, Dexcoms chairman, president and CEO.

Medpace Holdings, Inc. Reports Third Quarter 2020 Results

Biotechnology, Medical devices, Health, Pharmaceutical, Clinical trials

Monday, October 26, 2020 - 8:15pm

Key Points:

PerkinElmer Launches Industry First No-Wash Immunoassay For Phospho Ubiquitin Ser65 to Help Drive Neuroscience Disease and Therapeutics Research Forward

Biotechnology, Pharmaceutical, Health, Medical devices, Branches of biology, Immunoassay, Ubiquitin, Biology, Neuroscience, PerkinElmer

Monday, October 26, 2020 - 6:59pm

With this new immunoassay, researchers now have a more efficient and effective way to study a key biomarker which could lead to exciting new therapeutic candidates.

Key Points:

With this new immunoassay, researchers now have a more efficient and effective way to study a key biomarker which could lead to exciting new therapeutic candidates.
The new PerkinElmer Cisbio HTRF Phospho-Ubiquitin (Ser65) Cellular Kit, joins PerkinElmers range of immunoassay kits and reagents for neuroscience applications across HTRF, Alpha, LANCE and DELFIA.
For more information please visit: https://learn.cisbio.com/lp/guide-neurodegenerative-diseases-and-neuroin... ; https://uk.cisbio.eu/dd/by-universe/neuroscience
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare.
We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise.

Company Profile for Guided Therapeutics, Inc.

Health, Oncology, Medical devices, Infectious causes of cancer, Gynaecological cancer, Cervical cancer, Cancer, Clinical medicine, Health, Papillomavirus, Medical specialties

Monday, October 26, 2020 - 4:35pm

Guided Therapeutics, Inc. (OTCQB: GTHP) has developed a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level.

Key Points:

Guided Therapeutics, Inc. (OTCQB: GTHP) has developed a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level.
The companys first product, LuViva, is a non-invasive device used to detect cervical disease instantly and at the point of care.
In a multi-center clinical trial, with women at risk for cervical disease, LuViva was able to detect cervical cancer up to two years earlier than conventional tests.
LuViva is designed to provide an objective result at the point-of-care, thereby improving the management of cervical disease: www.guidedinc.com .

Shimmer Solicits Clinical Research Community Input on Expanded Open Wearables Initiative (OWEAR) Vision

Monday, October 26, 2020 - 4:07pm

Shimmer Research, a global leader in wearable technology for research applications, today announced that the Open Wearables Initiative (OWEAR) is evaluating a significant expansion of its vision and seeking industry input to build consensus.

Key Points:

Shimmer Research, a global leader in wearable technology for research applications, today announced that the Open Wearables Initiative (OWEAR) is evaluating a significant expansion of its vision and seeking industry input to build consensus.
OWEAR was founded in Sept. 2019 as an industry collaboration to promote the effective use of high-quality, sensor-generated measures of health in clinical research.
OWEAR has already achieved much of its original vision, building a community at www.owear.org which makes open source algorithms and wearable datasets more accessible, and instituting a benchmarking program to evaluate algorithms.
As OWEAR is most effective when we all work together, we decided to solicit input from the entire clinical research community to shape our expanded vision.